Carbamazepine for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Leucht, Stefan ^a   Kissling, W ^b   McGrath, J ^b   White, P ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

Antimanic agents *therapeutic use ; Carbamazepine *therapeutic use ; Humans; Randomized controlled trials as topic; Schizophrenia *drug therapy

Indexed keywords

ANTIPARKINSON AGENT; BIPERIDEN; BROMOCRIPTINE; CARBAMAZEPINE; CHLORPROTHIXENE; CLOZAPINE; CYPROHEPTADINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OXCARBAZEPINE; PERPHENAZINE; PLACEBO;

AKATHISIA; ALLERGIC REACTION; BLOOD DYSCRASIA; BLURRED VISION; CLINICAL TRIAL; COCHRANE LIBRARY; COLLAPSE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DATA BASE; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ECG ABNORMALITY; EEG ABNORMALITY; EMBASE; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MEDLINE; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; PARKINSONISM; PSYCINFO; RASH; RELAPSE; REVIEW; SALIVATION; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; XEROSTOMIA;

EID: 40049104877     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001258.pub2     Document Type: Review

References (154)

1. Carpenter 1991 {published data only} Carpenter WT, Kurz R, Kirkpatrick B, Hanlon TE. Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General Psychiatry 1991;48(1):69-72.
2. Dose 1987 {published data only} Dose M. Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991.
3. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research 1987;22(4):303-10.
4. Dose M, Emrich HM. Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research 1988;1(2,3):207-8.
5. Dose M, Emrich HM. Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift 1990;132 (suppl 1):87-90.
6. Dose M, Garcia D, Weber M, Yassouridis A, Emrich HM. Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry 1989;22(5):195.
7. Heßlinger 1998 {published and unpublished data} Hesslinger B, Klose P, Normann C, Langosch JM, Berger M, Walden J. Carbamazepine co-treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie 1998;66(4):145-50.
8. Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999;19(4):310-5.
9. Normann C, Klose P, Hesslinger B, Langosch JM, Berger M, Walden J. Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co-medication: a clinical trial. Pharmacopsychiatry 1997;30:204.
10. Walden J, Hesslinger B, Normann C, Langosch J, Berger M. Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland. 1998.
11. Llorca 1993 {published data only} Estorges JP, Llorca PM, Lancon C, Bougerol T, Scotto JC. Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients. Encephale 1991;Volume is unknown:page numbers are unknown.
12. Llorca PM, Wolf MA, Lancon C, Bougerol T. Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics [Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants]. Encephale 1993;19(5):565-71.
13. Mair 1990 {published data only} Mair M, Tschapeller I, Schubert H. Kombinationstherapie mit Neuroleptika und Carbamazepin. Eine kontrollierte Studie. In: SchonbeckG, PlatzT editor(s). Schizophrenie erkennen, verstehen, behandeln. Beiträge aus Theorie und Praxis. Wien: Springer Verlag, 1990: 77-92.
14. Martin-Munoz 1989 {published data only} Martin-Munoz JC, Morinigo-Dominguez AV, Mateo-Martin I, Guajardo FI. La carbamacepina: un tratamiento adjunto eficaz en las esquizofrenias. (Carbamazepine: An effective adjunct treatment for schizophrenia.). Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines 1992;20(1):11-6.
15. Martin-Munoz JC, Morinigo-Dominguez AV, Mateo-Martin I, Ibarra IG. La carbamacepina: Un tratamiento adjunto eficaz en las esquizofrenias. / Carbamazepine: An efficacious adjuvant treatment in schizophrenia. Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines 1989;17(4): 245-50.
16. Nachshoni 1994 {published data only} Nachshoni T, Levin Y, Levy A, Kritz A. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biological Psychiatry 1994;35(1):22-6.
17. Neppe 1983 {published and unpublished data} Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry 1983;44(9):326-31.
18. Neppe VM. Carbamazepine in the psychiatric patient. Lancet 1982; 2(8293):334.
19. Neppe VM. Non-responsive psychosis - a biochemical difference?. South African Medical Journal 1983;63(21):797-8.
20. Simhandl 1996 {published data only} Meszaros K, Simhandl C, Denk E, Liechtenstein A, Topitz A, Thau K. A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. 1996;n/a:na/a.
21. Simhandl C, Meszaros K, Denk E, Thau K, Topitz A. Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia [2]. Canadian Journal of Psychiatry/ Revue Canadienne de Psychiatrie 1996;41(5):317.
22. Svestka 1989 {published data only} Svestka J, Ceskova E, Rysanek R, Nahunek K. Controlled cross-over comparison of carbamazepine with perphenazine in schizophrenic psychoses. Activitas Nervosa Superior 1989;31(4):276-7.
23. Arana 1986 Arana GW. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? 138th Annual Meeting of the American Psychiatric Association (1985, Dallas, Texas). American Journal of Psychiatry 1986;143(5):650-1.
24. Azorin 1986 Azorin JM, Samuelian JC, Pringuey D, Donnet A. Place de la carbamazepine dans le traitement des psychoses endogenes: Resultats d'une etude ouverte. / Place of carbamazepine in the treatment of endogenous psychoses: Results of an open trial. Encephale 1986;12 (3):115-9.
25. Ballenger 1984 Ballenger JC, Post RM. Carbamazepine in alcohol and withdrawal syndromes and schizophrenic psychoses. Psychopharmacology Bulletin 1984;20:572-584.
26. Barnes 1996 Barnes TR, McEvedy CJ. Pharmacological treatment strategies in the non-responsive schizophrenic patient. International Clinical Psychopharmacology 1996;11(s2):67-71.
27. Bellaire 1990 Bellaire W, Demisch K, Stoll K-D. Carbamazepine vs. lithium. Application in the prophylaxis of recidivating affective and schizoaffective psychoses Carbamazepine vs. lithium. Application in the prophylaxis of recidivating affective and schizoaffective psychoses [Carbamazepin vs. Lithium. Einsatz in der Prophylaxe rezidivierender affektiver und schizoaffektiver Psychosen]. Münchner Medizinische Wochenschrift 1990;132:82-6.
28. Birkheimer 1985 Birkhimer LJ, Curtis JL, Jann MW. Use of carbamazepine in psychiatric disorders. Clinical Pharmacology 1985;4(4):425-34.
29. Borison 1991 Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin 1991;27(2):103-6. [MEDLINE: 92021349].
30. Botte 1988 Botte L, Charles G. Utilisations cliniques de la carbamazepine: Revue de la litterature et resultats personnels. / Clinical use of carbamazepine: Review from the literature and personal results. Acta Psychiatrica Belgica 1988;88(3):181-94.
31. Cabrera 1986 Cabrera J, Albrecht J, Muller-Oerlinghausen B. Combined preventive treatment of recurrent manic-depressive disease with lithium and carbamazepine or oxcarbazepine. Nervenarzt 1987;58(4):245-9.
32. Cegalis 1984 Cegalis JA, Possick SG. Carbamazepine and psychotherapy in the treatment of schizoaffective psychosis. Yale Journal of Biology and Medicine 1985;58(4):327-36.
33. Chouinard 1990 Chouinard G, Sultan S. Treatment of supersensitivity psychosis with antiepileptic drugs: Report of a series of 43 cases. Psychopharmacology Bulletin 1990;26(3):337.
34. Costa 1986 Costa JF, Sramek J, Herrera JM. Hepatic reaction to carbamazepine. Journal of Clinical Psychopharmacology 1986;6(4):251-2.
35. Covell 2004 Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophrenia Bulletin 2004;30(2):229-40. [MEDLINE: 15279042].
36. Dalby 1971 Dalby MA. Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971;12(12):335-40.
37. de Vogelaer 1981 de Vogelaer J. Carbamazepine in the treatment of psychotic and behavioral disorders. A pilot study. Acta psychiatrica belgica 1981;81:532-541.
38. Dehing 1968 Dehing J. Studies on the psychotropic action of tegretol. Acta Neurologica Belgica 1968;68:895-905.
39. Denicoff 1994 Denicoff KD, Meglathery SB, Post RM, Tandeciarz SI. Efficacy of carbamazepine compared with other agents: A clinical practice survey. Journal of Clinical Psychiatry 1994;55(2):70.
40. Elphick 1985 Elphick M. An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics. British Journal of Psychiatry 1985;147:198-200.
41. Frankenburg 1988 Frankenburg FR, Tohen M, Cohen BM, Lipinski JF. Long-term response to carbamazepine: A retrospective study. Journal of Clinical Psychopharmacology 1988;8(2):130-2.
42. Gadow 1992 Gadow KD. Pediatric psychopharmacotherapy: A review of recent research. Journal of Child Psychology and Psychiatry and Allied Disciplines 1992;33(1):153-95.
43. Galletly 1997 Galletly CA, Tsourtos G. Antipsychotic drug doses and adjunctive drugs in the outpatient treatment of schizophrenia. Annals of Clinical Psychiatry 1997;9(2):77-80.
44. Ginestet 1996 Ginestet D, Ghanem T, Slama M. The variety of indications for carbamazepine. Revue du Praticien Medecine Generale 1996;10(336):11.
45. Goncalves 1985 Goncalves N, Stoll KD. A controlled double-blind trial of carbamazepine in manic illness [Carbamazepin bei manischen Syndromen. Eine kontrollierte Doppelblind-Studie]. Nervenarzt 1985;56(1):43- 7.
46. Greil 1997 Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR. Lithium vs cambamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. European Archives of Psychiatry and Clinical Neuroscience 1997;247(1):42-50.
47. Hakola 1982 Hakola HA, Laulumaa VA. Carbamazepine in treatment of violent schizophrenics. Lancet 1982;1(8285):1358.
48. Hermle 1993 Hermle L, Spitzer M. Succesful desensitization of a patient with schizoaffective psychosis and carbamazepin allergy. Nervenarzt 1993;64(3):208.
49. Herrera 1987 Heh CW, Sramek J, Herrera J, Costa J. Exacerbation of psychosis after discontinuation of carbamazepine treatment. American Journal of Psychiatry 1988;145(7):878-9.
50. Herrera JM, Sramek JJ, Costa JF. Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug Intell Clin Pharm 1987;21(4):355-8.
51. Iwahashi 1995 Iwahashi K, Miyatake R, Suwaki H, Hosokawa K. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clinical Neuropharmacology 1995;18(3):233-6.
52. Iwahashi 1996 Iwahashi K. Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change [see comments]. Clinical Neuropharmacology 1996;19(3):267-70.
53. Jann 1985 Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, Burch NR, Bowden CL. Effects of carbamazepine on plasma haloperidol levels. Journal of Clinical Psychopharmacology 1985;5(2):106-9.
54. Johns 1995 Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy. Schizophrenia Bulletin 1995;21(4):607-19.
55. Kahn 1990 *Kahn EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia. Journal of Clinical Psychopharmacology 1990;10(1):54-7.
56. Karper 1992 Karper LP, Seibyl JP, Krystal JH. Valproate management of psychosis in a patient with carbamazepine-induced hyponatremia. Journal of Clinical Psychopharmacology 1992;12(2):137-9.
57. Keck 1996 Keck PE, McElroy SL, Strakowski SM. New developments in the pharmacologic treatment of schizoaffective disorder. Journal of Clinical Psychiatry 1996;57(s9):41-8.
58. Kessler 1989 Kessler AJ, Barklage NE, Jefferson JW. Mood disorders in the psychoneurologic borderland: Three cases of responsiveness to carbamazepine. 29th Annual Meeting of the International Psychiatric Research Society (1987, Madison, Wisconsin). American Journal of Psychiatry 1989;146(1):81-3.
59. Kidron 1985 Kidron R, Averbuch I, Klein E, Belmaker RH. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biological Psychiatry 1985;20(2):219-22.
60. Klein 1984 Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Archives of General Psychiatry 1984;41(2):165-70.
61. Kraft 1984 Kraft AM, Hassenfeld IN, Zarr M. Response to functional hallucinations to carbamazepine. American Journal of Psychiatry 1984;141(8):1018.
62. Lambert 1987 Lambert PA, Venaud G. Use of valpromide in psychiatric therapeutics. Encephale 1987;13(6):367-73.
63. Lapensee 1992 Lapensee MA. A review of schizoaffective disorder: II. Somatic treatment. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie 1992;37(5):347.
64. Lenzi 1986 Lenzi A, Lazzerini F, Grossi E, et al.Use of carbamazepine in acute psychosis: A controlled study. Journal of International Medical Research 1986;14(2):78-84.
65. Llorca 1992 Llorca PM, Wolf MA, Lancon C, Bougerol T. Adjuvant drugs for use in patients under neuroleptics. Annales de Psychiatrie 1992;7(4):195.
66. Luchins 1983 Luchins DJ. Carbamazepine for the violent psychiatric patient. Lancet 1983;1(8327):766.
67. Luchins DJ. Carbamazepine in violent nonepileptic schizophrenics. Psychopharmacology Bulletin 1984;20(3):569-571.
68. Luchins 1984 Luchins DJ. Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. American Journal of Psychiatry 1984;141(5):687-8.
69. Makaric 2000 Makaric G, Folnegovic-Smalc V, Folnegovic Z, Imica N. Agitation in acute episode of schizophrenia: carbamazepine treatment in combination with haloperidol versus combined neuroleptics. Schizophrenia Research 2000;41(1):210. [MEDLINE: 1999367069].
70. McAllister 1985 McAllister TW. Carbamazepine in mixed frontal lobe and psychiatric disorders. Journal of Clinical Psychiatry 1985;46(9):393-4.
71. McKee 1989 McKee RW, Larkin JG, Brodie MJ. Acute psychosis with carbamazepine and sodium valproate. Lancet 1989;1(8630):167.
72. Meltzer 1992 Meltzer HY. Novel approaches to the pharmacotherapy of schizophrenia. Drug Development Research 1986;9(1):23-40.
73. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin 1992;18(3):515-42.
74. Meshel 1967 Meshel E, Denber HC. Double-blind study of tybamate in psychotic patients. Diseases of the Nervous System 1967;28(5): 311-3. [MEDLINE: 67165839].
75. Meshel 1968 Meshel E, Denber HC. The use of tybamate in psychotic patients. (A further double blind study). Diseases of the Nervous System 1968;29(4):243-5. [MEDLINE: 68271597].
76. Miceli 2000 *Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. British Journal of Clinical Pharmacology 2000; 49 (suppl I):65S-70S.
77. Miller 1965 Miller MJ, Shettel R, Fiedler HT. Chronic toxicologic evaluation of hydroxyphenamate and possible synergism with phenothiazines. Psychosomatics 1965;6(5):340-2. [MEDLINE: 66013834].
78. Miodownik 2003 Miodownik C, Cohen H, Kotler M, Lerner V. Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah 2003;142(8-9):592-6, 647. [MEDLINE: 14518160].
79. Mokrusch 1987 Mokrusch T, Negele J, Kaschka WP. New aspects in the prophylaxis of affective and schizoaffective psychoses. Fortschritte der Medizin 1987;105(1):30-4.
80. Morinigo 1992 Morinigo A, Mateo I, Martin J, Noval D, Gonzalez S. Efectos terapeuticos del valproato sodico y la carbamacepina en lamania. Psiquis 1992;13(8):335-8.
81. Mosca 1998 Mosca LD//Licciardo JP//Coppola JL. A double-blind carbamazepine-controlled efficacy and safety study of valproate in impulsivity and violence. 11th Congress of The European College of Neuropsychopharmacology; Oct 31 - Nov 4, Paris, France. 1998.
82. Munetz 1989 Munetz MR, Schulz SC, Bellin M, Harty I. Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia. Drug Development Research 1989;16(1):79-83. [MEDLINE: 83197879].
83. Möller 1989 Moller HJ, Kissling W, Riehl T, Bauml J. Double-blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Progress in Neuropsychopharmacology and Biological Psychiatry 1989;13(1-2):127-36.
84. Möller 1996 Moller H. Treatment of schizophrenia. State of the art. European Archives of Psychiatry and Clinical Neuroscience 1996;246(5):229.
85. Nasser 1990 Nasser D, Thomas B. Anticonvulsant treatment of psychoses. Australian and New Zealand Journal of Psychiatry 1990;24(2):164.
86. Nelson 1993 Nelson JC. Combined treatment strategies in psychiatry. Journal of Clinical Psychiatry 1993;54(s9):42.
87. Neppe 1988a Neppe VM. Carbamazepine in nonresponsive psychosis. Journal of Clinical Psychiatry 1988;49(s):22-8.
88. Neppe 1988b Neppe VM, Tucker GJ, Wilensky AJ. Fundamentals of carbamazepine use in neuropsychiatry. Journal of Clinical Psychiatry 1988;49(s):4-6.
89. Neppe 1988c Neppe VM. Carbamazepine for withdrawal pseudohallucinations. American Journal of Psychiatry 1988;145(12): 1605.
90. Neppe 1991 Neppe VM, Bowman BR, Sawchuk KS. Carbamazepine for atypical psychosis with episodic hostility. Journal of Nervous and Mental Disease 1991;179(7):439-41.
91. Nijdam 1992 Nijdam JR, Doorschot CH, van Bavel LP, Loonen AJ. A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients. Pharmacopsychiatry 1992; 25(3):145-9. [MEDLINE: 92342659].
92. Okuma 1989a Okuma T, Yamashita I, Takahashi R, Itoh H. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatrica Scandinavica 1989;80(3):250-9.
93. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Ozama H, Inanaga K. Comparison of the therapeutic effect of carbamazepine and placebo in schizophrenia and atypical psychosis by double blind controlled study. Rinsho Hyoka 1988;16 (2):327-73.
94. Okuma 1989b Okuma T, Yamashita I, Takahashi R, Itoh H. Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders. Pharmacopsychiatry 1989;22(2):47-53.
95. Ortega 1991 Hernandez-Avila CA, Ortega-Soto HA, Jasso A, Hasfura-Buenaga CA, Kranzler HR. Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol. Psychiatric Services 1998;49:812-15.
96. Ortega SHA, Jasso A, Cecena G, Hernandez ACA. Validity and reproductivity of a scale for measuring neuroleptic-induced extrapyramidal symptoms [La validez y la reproducibilidad de dos escalas para evaluar los sintomas extrapiramidales inducidos por neurolepticos]. Salud Mental 1991;14(3):1-5.
97. Otani 1997 Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, Furukori H, Kaneko S, Inoue Y. Interaction between carbamazepine and bromperidol. European Journal of Clinical Pharmacology 1997; 52(3):219.
98. Pantelis 1996 Pantelis C, Barnes TR. Drug strategies and treatment-resistant schizophrenia. Australian and New Zealand Journal of Psychiatry 1996; 30(1):20-37.
99. Panu 1984 Panu H, Hakola A, Laulumaa VA. Carbamazepine in violent schizophrenics. In: EmrichHM, OkumaT editor(s). Anticonvulsants in affective disorders. Amsterdam: Elsevier, 1984:204-7.
100. Placidi 1986 Placidi GF, Lenzi A, Lazzerini F, Cassano GB. The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. Journal of Clinical Psychiatry 1986;47(10):490-4.
101. Placidi GF, Lenzi A, Rampello E, Andreani MF, Cassano GB, Grossi E. Long term-double blind prospective study on carbamazepine versus lithium in bipolar and schizoaffective disorders. Preliminary results. Anticonvulsants in affective disorders. Amsterdam: Elsevier, 1984: 188-97.
102. Placidi GF, Lenzi A, Rampello E, Andreani MF, Cassano GB, Grossi E. Long term-double blind prospective study on carbamazepine versus lithium in bipolar and schizoaffective disorders. Preliminary results. In: EmrichHM, OkumaT editor(s). Anticonvulsants in affective disorders. Amsterdam: Elsevier, 1984:188-97.
103. Raitasuo 1994 Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics: A case report. Psychopharmacology 1994;116(1):115-6.
104. Rankel 1988 Rankel HW, Rankel LE. Carbamazepine in the treatment of catatonia. American Journal of Psychiatry 1988;145(3):361-2.
105. Rittmannsberger 1990 Rittmannsberger H. Carbamazepine in the treatment of psychiatric illness: Effects and side effects. Wiener Medizinische Wochenschrift 1990;140(15):398.
106. Scher 1983 Scher M, Neppe V. Carbamazepine adjunct for nonresponsive psychosis with prior hallucinogenic abuse. Journal of Nervous and Mental Disease 1989;177(12):755.
107. Schulz 1990 Schulz SC, Conley RR, Kahn EM, et al.Nonresponders to neuroleptics: a distinct subtype. Schizophrenia: scientific progress. New York: Oxford University Press, Date of publication and page numbers not indicated.
108. Schulz SC, Kahn EM, Baker RW, et al.Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. The neuroleptic- nonresponsive patient: Characterization and treatment. Washington DC: American Psychiatric Press, 1990:111-36.
109. Simhandl 1992 Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: A review. Journal of Psychiatry and Neuroscience 1992;17(1):1-14.
110. Siris 1993 Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. British Journal of Psychiatry 1993;163(s22):22-78.
111. Sramek 1988 Heh CW, Potkin SG, Pickar D, Costa J, Herrera J, Sramek J, DeMet E. Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics. Biological Psychiatry 1989;25(5):639-41.
112. Herrera J, Sramek J, Costa C, Heh C, Wernberg C. An evaluation of carbamazepine (Tegretol) in chronic treatment-refractory schizophrenia. Proceedings of the 95th Annual Conference of the American Psychiatric Association. 1987:588-9.
113. Sramek J, Herrera J, Costa J, Heh C, Tran Johnson T, Simpson G. A carbamazepine trial in chronic, treatment-refractory schizophrenia. American Journal of Psychiatry 1988;145(6):748-50.
114. Tran-Johnson T, Sramek JJ, Walker NR, Heh CD, Costa JF, Herrera JM. Effects of carbamazepine on serum calcium in schizophrenia. DICP 1989;23(12):1034.
115. Sugerman 1970 Sugerman AA, Hyams L. Electroencephalographic effects of adrenochrome semicarbazone in schizophrenia: quantitative amplitude analysis. Research Communications in Chemical Pathology and Pharmacology 1970;1(1):86-98. [MEDLINE: 72091267].
116. Svestka 1985 Svestka J, Nahunek K, Ceskova E, Korbicka J. Carbamazepine prophylaxis of affective psychoses: Intraindividual comparison with lithium carbonate. 27th Annual Psychopharmacology Meeting (1985, Jesenik, Czechoslovakia). Activitas Nervosa Superior 1985;27 (4):261-2.
117. Svestka 1988 Svestka J, Nahunek K, Ceskova E. Pouziti carbamazepinu v lecbe a profylaxi afektivnich psychoz. / Carbamazepine in the treatment and prophylaxis of affective psychoses. Ceskoslovenska Psychiatrie 1988;84 (3):145-55.
118. Tohen 1994 Tohen M, Castillo J, Pope HG, Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. Journal of Clinical Psychopharmacology 1994;14(1):67.
119. Walden 1996 Walden J, Von WJ, Berger M, Grunze H. Efficacy of antiepileptic drugs in the treatment of psychiatric diseases. EEG Labor 1996;18 (1):32.
120. Wetterling 1987 Wetterling T. Open clinical trial of carbamazepine in chronic schizophrenic inpatients. Pharmacopsychiatry 1987;20(3):127-30.
121. Wunderlich 1983 Wunderlich HP, Grunes JU, Neumann J, Zahlten W. Carbamazepine (Finlepsin(TM)) for manicdepressive and schizophrenic diseases. Deutsche Gesundheitswesen 1983;38(35):1352-6.
122. Yassa 1983 Yassa R, Dupont D. Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: A case report. Canadian Journal of Psychiatry 1983;28(7):566-8.
123. Kamisada 1988 Kamisada M, Tateyama M, Nakano Y, Kawachi Y, Fujii Y, Tanoue A, Takamiya M, Nakajima S, Sakuma K, Oguchi E, Yagi G. Comparison of the Clinical Effects of Lithium Carbonate and Carbamazepine on Excited Schizophrenics. Psychopharmacology 1988;96 (Suppl):348. [MEDLINE: 72091267].
124. Lee 1996 Lee MS, Choi BH, Kim SH. Combined use of carbamazepine and valproic acid in negative symptom schizophrenia. 9th Congress of the European College of Neuropsychopharmacology; September 21-25, Amsterdam, The Netherlands. 1996.
125. Ahonen 1998 Ahonen J, Cheine M, Wahlbeck K. Supplementing standard drug treatment of those with schizophrenia with beta-blocking medication (Cochrane Review). Cochrane Database of Systematic Reviews 1998, Issue Issue 2.
126. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
127. Andreasen 1982 Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry 1982;39:784-8.
128. Andreasen 1984 Andreasen NC. The scale for assessment of positive symptoms. University of Iowa 1984.
129. Begg 1996 Beg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9.
130. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
131. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
132. Christison 1991 Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 1991;17:217-45.
133. Dardennes 1995 Dardennes R, Even C, Bange F, Heim A. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorder: a meta-analysis. British Journal of Psychiatry 1995;166:378-81.
134. Davey Smith 1998 Davey Smith G, Egger M. Meta-analysis: Unresolved issues and future developments. BMJ 1998;16:221-5.
135. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
136. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
137. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
138. Egger 1997 Egger M, Davey mith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
139. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
140. Hamilton 1960 Hamilton M. A rating scale of depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
141. Higgins 2005 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. CochraneDatabase of Systematic Reviews 2005, Issue 3.
142. Jadad 1996 Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavanagh DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
143. Kane 1988 Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative study group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-96.
144. Kay 1987 Kay SR, Fiszbein A. The positive and negative symptome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-75.
145. Lorr 1962 Lorr M, McNair DM, Klett CJ, Lasky JJ. Evidence of ten psychotic symptoms. Journal of Consulting Psychology 1962;26:185.
146. NIMH 1970 Clinical global impression. Manual for the ECDEU Assessment Battery 1970.
147. Overall 1962 Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:790-812.
148. Schooler 1993 Schooler NR, Keith SJ. Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29:431-46.
149. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
150. Tharyan 2002 Tharyan P. Electroconvulsive therapy for schizophrenia (Cochrane Review). Cochrane Database of Systematic Reviews 2002, Issue 1.Art. No.: CD000076. DOI:10.1002/14651858.CD000076.pub2.
151. Tiihonen 1995 Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995;28:26-8.
152. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317].
153. Wahlbeck 1998 Wahlbeck K, Cheine M, Essali MA, Rezk E. Clozapine vs 'typical' neuroleptic medication for schizophrenia (Cochrane Review). Cochrane Database of Systematic Reviews 1998, Issue 2.
154. Leucht 2002 Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence?. Journal of Clinical Psychiatry 2002;63(3):218-24.